Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 23;24(11):1416–1419. doi: 10.1634/theoncologist.2018-0686

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Positron emission tomography and computed tomography (PET/CT) throughout treatment. (A): PET/CT prior to initiating pembrolizumab. (B): PET/CT after 5 months of immunotherapy indicating a partial response with decrease in standardized uptake value (SUV) of liver mass from 6.5 down to 4.6. (C): PET imaging at time of progression after atezolizumab and pembrolizumab with maximum SUV of 6.5. (D): PET obtained after 8 months on ipilimumab plus nivolumab for four doses followed by nivolumab alone showed a response to combination therapy with a maximum SUV of 3.6.